Our upcoming Keiretsu Forum SoCal Investor Forum—in-person—will showcase a curated lineup of companies operating at the edge of innovation.
We review substantial deal flow, but only a select few are invited to present.
Expect:
• Focused, investor-ready 5-minute presentations
• Speed Match with Investors and Entrepreneurs
• Syndication opportunities across our global network
• Direct access to founders building what’s next
This is where alignment happens—before capital moves.
Join us.
Location: The California Club, Downtown LA
538 South Flower, ST. LA, CA 90071
Dress Code: Jackets for Men, Collared Shirts, Slacks, Khakis, or Tasteful Denim, not distressed, ripped or defaced. NO t-shirts, shorts, hoodies, athletic shoes, sneakers hats, or flip flops
Auragen is a material-driven platform developing collagen nano-infused textiles that deliver hydration, odor control, and UV protection at the fiber level. Initially launching in medical apparel, the company leverages exclusive North American access to Filagen technology to redefine performance wear and expand across multiple verticals.
Engraft Technologies is commercializing the first fully closed-loop robotic hair transplant system, cutting surgery time from 10 hours to under 3 and halving required staff. Founded by the pioneers of FUE and NeoGraft, and protected by five US patents, we're targeting a $10 billion market with no dominant player.
Innova NanoJet® Technologies Ltd. a UK/US commercial-stage deep technology company, is redefining air safety with NanoJet®—a patented, filter-less aerosol platform designed for active airborne pathogen management. Our first commercial product, AirSancta® CDa, delivers rapid, whole-room purification and disinfection using water-based nano-atomization, offering structural cost and performance advantages over HEPA systems. With NHS England procurement framework acceptance, validated lab results, and scalable manufacturing in place, we are accelerating global commercialization of a category-defining technology.
KizaVie™ (LEAF-4L6715) is a late-stage, first-in-class therapeutic platform designed to restore oxygen diffusion at the microvascular level—addressing a fundamental physiological limitation that drives mortality, treatment resistance, and healthcare burden across critical care, oncology, trauma, and chronic disease. Unlike conventional therapies that increase oxygen supply, KizaVie™ enables oxygen delivery at the tissue level, directly targeting a core biological failure not addressed by current standards of care.
OmniPad is the world's only patented, circular revolving-tread, omnidirectional human locomotion system. It combines virtual reality with cardiovascular exercise and rehabilitation, industrial and military training and much more.
Stronghold Systems is transforming classroom safety with a rapidly deployable in-classroom protection system designed to secure students and teachers during the critical minutes between alert and response. Addressing a massive and urgent market need, Stronghold combines strong parent and educator demand, existing school funding pathways, high-margin recurring revenue, and scalable deployment potential to define a new category in school safety infrastructure.
Cloud K9 is acquiring a 14,000 square-foot veterinary facility in Santa Clarita that generates $1.6 million a year from one veterinarian, at 19% boarding occupancy, with its highest-margin service hidden from customers. They're taking it to $3.72 million in 24 months. The real estate alone is worth more than they are paying.
PhotonWeave is redefining AI infrastructure with its ATHENA PhaseWeave optical interconnect platform, replacing copper with ultra efficient micro LED technology. By slashing rack power, reducing cooling needs, and enabling massive bandwidth, PhotonWeave addresses the AI energy crisis while offering scalable, manufacturable solutions validated by top semiconductor partners and driven by world class photonics expertise.
Relief Compass is a purpose-built platform that streamlines resource distribution and last-mile delivery, ensuring critical supplies and services reach survivors quickly and efficiently. Beyond supporting rapid response, the platform captures unmet needs in real time, enhances coordination, improves donations and warehouse management, strengthens case management, and helps organizations prioritize life-saving actions.
Exactice Medical is developing the AIM™ device, a patented breakthrough technology designed to make transseptal cardiac procedures faster, safer, and more efficient by integrating real-time imaging with a steerable access needle into a single device. Targeting a rapidly growing multibillion-dollar market, Exactice combines strong clinical validation, experienced leadership, and significant strategic acquisition potential.
Pilot scale production of Omega Power Safe™ fireproof batteries will lead to a fast-track to revenue with their U.S. based manufacturing partnerships. Follow on Series A funding of $25M will lead to commercial scale production capacity to ramp up annual revenue to over $100M. This gives Omega Power a first-movers advantage in targeting the non-EV, power hungry AI robotics and drone markets, prioritizing safety, using their licensed and patented components and proprietary non-flammable electrolyte to supply these highly profitable, yet underserved market segments looking to transition to a “Made in America” cell supplier to avoid tariff and supply chain risks.
Pharma in silica’s precision chemotherapy attacks solid tumors while sparing patients painful, maiming and costly adverse effects imposed by current chemo. OpPacli™ is fifteen months to FDA Phase Ib/IIa 515(b)(2) clinical trial against NSCLC. In 2028, the nanocarrier platform will enable pharmas to capture the chemo drugs US$ 25B market.
QuantaPro enables oncologists to determine—early and in real time—whether chemotherapy will work, using a single drop of blood. Beginning with the ERCC1 chemo-resistance test, the company addresses a long-standing clinical blind spot in oncology while building a scalable, high-margin proteomic testing platform that will expand to other chronic diseases.